FBRX News and Press, Forte Biosciences Inc.

2026-04-10 15:27:12 ET I'm initiating Forte Biosciences ( FBRX ) with a "Hold" rating. The reason why I'm doing so is because even though in the past it had a rough failure with another candidate by the name of FB401 it might be able to potentially recover with another candidate...

2026-04-10 14:15:40 ET Investment Overview The stock of Dallas, Texas-based biotech Forte Biosciences ( FBRX ) is up by a remarkable 480% on a 12-month basis and up >120% on a six-month basis. Shares are also up >35% this week, apparently due to a fundraising a...

2026-04-09 10:00:02 ET Forte Biosciences, Inc. (NASDAQ: FBRX) is one of today’s top gainers. The company’s shares have moved 20.52% on the day to $31.66. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developi...

2026-04-09 04:50:52 ET Forte Biosciences ( FBRX ) has announced pricing of a public offering of 5.71M shares of its common stock at $26.27 per share, with expected gross proceeds from the offering to be around $150M. ... Read the full article on Seeking Alpha ...

Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has g...

2026-04-08 16:05:19 ET More on Forte Biosciences Forte Biosciences GAAP EPS of -$4.71 Seeking Alpha’s Quant Rating on Forte Biosciences Historical earnings data for Forte Biosciences Financial information for Forte Biosciences Read the full a...

2026-03-31 16:49:25 ET More on Forte Biosciences Seeking Alpha’s Quant Rating on Forte Biosciences Historical earnings data for Forte Biosciences Financial information for Forte Biosciences Read the full article on Seeking Alpha For further det...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and provided a business update. “The clinical development for FB102 ...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announ...

2025-11-25 07:06:57 ET from Evercore ISI issued a price target of $65.00 for FBRX on 2025-11-25 11:34:55. The adjusted price target was set to $65.00. At the time of the announcement, FBRX was trading at $19.06. FBRX currently trades -33.54% versus its 52 week high of $2...